SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ionis Pharmaceuticals (IONS)
IONS 80.40-1.4%Jan 9 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sonny who wrote (2195)8/11/1998 1:17:00 AM
From: Adrian Wu  Read Replies (1) of 4676
 
Sonny,

Isis is very focused on antisense technology. They should be at this stage since they don't have the resources to work on too many fronts. When they get to Amgen's stage of development, which is about 5 years from now, they can afford to invest in other promising technologies. I think they are very interested in apoptosis. It is interesting to note the guy who first described apoptosis in the 70s- Andrew Wyllie- was my supervisor, but everybody thought he was in the looney fringe for the longest time until apoptosis became hot in the mid eighties. I'm quite sure there is great potential in blocking certain genes such as p53, Bcl2, Bclx, c-myc etc. in the treatment of cancer. The trick is to target only those cells that express these genes inappropriately or in abnormally large amounts.

Adrian
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News